I have established one of the largest oncology phase I centers in Asia for more than 10 years. I played a very important role in developing novel chemotherapies, e.g. TLC388 (topoisomerase I inhibitor), trastuzumab deruxtecan (DS8201, anti-HER2 antibody drug conjugate); and targeted therapies, e.g. volasertib (BI6727, polo-like kinase inhibitor), xentuzumab (BI836845, anti-IGF antibody), BI853520 (FAK inhibitor), vismodegib (LDE225, SMO inhibitor), osimertinib (AZD9291, EGFR inhibitor), TSR011 (ALK inhibitor), plexidartinib (PLX3397, CSF1R inhibitor). In recent years, we were also heavily involved in developing novel immunotherapies, e.g. pembrolizumab (MK3475, anti-PD1 antibody) in head and neck cancer, gastric cancer; spartalizumab (PDR001, anti-PD1 antibody) in malignant melanoma, non-small cell lung cancer, anaplastic thyroid cancer; spartalizumab (PDR001, anti-PD1 antibody) + MBG453 (anti-TIM3 antibody) in malignant melanoma, non-small cell lung cancer; tislelizumab (BGB-A317, anti-PD1 antibody) in non-small cell lung cancer, esophageal cancer, gastric cancer, hepatocellular carcinoma; LY3300054 (anti-PD-L1 antibody) + LY3321367 (anti-TIM3 antibody) in MSI high colorectal cancer; bintrafusp alpha (MSB0011359C, anti-PD-L1 antibody + TGFβ trap); durvalumab (MEDI4736, anti-PD-L1 antibody) + ramucirumab (IMC1121B, anti-VEGFR antibody) in non-small cell lung cancer, gastric cancer, hepatocellular carcinoma.
